Publication:
Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC)

Simple item page
dc.contributor.authorMeijers, Wouter C. (56085653000)
dc.contributor.authorBayes-Genis, Antoni (7004094140)
dc.contributor.authorMebazaa, Alexandre (57210091243)
dc.contributor.authorBauersachs, Johann (7004626054)
dc.contributor.authorCleland, John G.F. (7202164137)
dc.contributor.authorCoats, Andrew J.S. (35395386900)
dc.contributor.authorJanuzzi, James L. (7003533511)
dc.contributor.authorMaisel, Alan S. (7004795386)
dc.contributor.authorMcDonald, Kenneth (57203044348)
dc.contributor.authorMueller, Thomas (59662788800)
dc.contributor.authorRichards, A. Mark (7402299599)
dc.contributor.authorSeferovic, Petar (6603594879)
dc.contributor.authorMueller, Christian (57638261900)
dc.contributor.authorde Boer, Rudolf A. (8572907800)
dc.date.accessioned2025-06-12T13:20:54Z
dc.date.available2025-06-12T13:20:54Z
dc.date.issued2021
dc.description.abstractNew biomarkers are being evaluated for their ability to advance the management of patients with heart failure. Despite a large pool of interesting candidate biomarkers, besides natriuretic peptides virtually none have succeeded in being applied into the clinical setting. In this review, we examine the most promising emerging candidates for clinical assessment and management of patients with heart failure. We discuss high-sensitivity cardiac troponins (Tn), procalcitonin, novel kidney markers, soluble suppression of tumorigenicity 2 (sST2), galectin-3, growth differentiation factor-15 (GDF-15), cluster of differentiation 146 (CD146), neprilysin, adrenomedullin (ADM), and also discuss proteomics and genetic-based risk scores. We focused on guidance and assistance with daily clinical care decision-making. For each biomarker, analytical considerations are discussed, as well as performance regarding diagnosis and prognosis. Furthermore, we discuss potential implementation in clinical algorithms and in ongoing clinical trials. © 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
dc.identifier.urihttps://doi.org/10.1002/ejhf.2346
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85116770015&doi=10.1002%2fejhf.2346&partnerID=40&md5=bd24fac5be3e1a66ad56c10a9dc4c798
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/4022
dc.subjectAdrenomedullin
dc.subjectBiomarkers
dc.subjectCardiac troponin
dc.subjectGalectin-3
dc.subjectGrowth differentiation factor-15
dc.subjectHeart failure
dc.subjectProcalcitonin
dc.subjectsST2
dc.titleCirculating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC)
dspace.entity.typePublication

Files

Collections

Publikacije / Publications